問卷

TPIDB > Search Result

Search Result

篩選

List

4Cases

2020-06-26 - 2026-12-31

Phase I/II

Active
A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants with HER2-Overexpressing Gastric Cancer (DESTINY-Gastric03)
  • Condition/Disease

    HER2 overexpressing locally advanced or metastatic, unresectable Gastric Cancer.

  • Test Drug

    Trastuzumab Deruxtecan

Participate Sites
6Sites

Recruiting6Sites

2021-10-22 - 2023-07-14

Phase II/III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-03-05 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites